ABBV - AbbVie Inc.
Close
174.83
0.250 0.143%
Share volume: 105,851
Last Updated: Fri 10 Jan 2025 08:30:00 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.49%
PREVIOUS CLOSE
CHG
CHG%
$174.58
0.25
0.14%
View ratios
| Fiscal Date | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | |
| Report Date | 2024-05-03 | 2023-08-07 | 2023-11-06 | 2024-11-04 | 2024-05-03 | 2024-08-07 | 2024-11-04 | |
| Total revenue | 12.225 B | 13.865 B | 13.927 B | 14.301 B | 12.310 B | 14.462 B | 14.460 B | |
| Cost of revenue | 4.136 B | 4.240 B | 6.551 B | 6.266 B | 4.258 B | 5.139 B | 4.212 B | |
| Gross profit | 8.089 B | 9.625 B | 7.376 B | 8.035 B | 8.052 B | 9.323 B | 10.248 B | |
| 18.99% | -23.37% | 8.93% | 0.21% | 15.78% | 9.92% | |||
| Operating expenses | 5.331 B | 5.281 B | 5.095 B | 4.840 B | 5.254 B | 5.325 B | 6.417 B | |
| Selling general and admin | 3.039 B | 3.548 B | 3.372 B | 2.913 B | 3.315 B | 3.377 B | 4.287 B | |
| Research and development | 2.292 B | 1.733 B | 1.723 B | 1.927 B | 1.939 B | 1.948 B | 2.130 B | |
| Total expenses | 5.321 B | 5.112 B | 5.095 B | 4.840 B | 5.254 B | 5.325 B | 6.417 B | |
| -3.93% | -0.33% | -5.00% | 8.55% | 1.35% | 20.51% | |||
| Operating income | 2.768 B | 4.513 B | 2.281 B | 3.195 B | 2.798 B | 3.998 B | 3.831 B | |
| Ebit | 929.000 M | 3.064 B | 2.351 B | 1.590 B | 2.208 B | 2.652 B | 2.675 B | |
| Pretax income | 475.000 M | 2.610 B | 1.953 B | 1.212 B | 1.755 B | 2.146 B | 2.084 B | |
| 449.47% | -25.17% | -37.94% | 44.80% | 22.28% | -2.89% | |||
| Income tax | 234.000 M | 583.000 M | 172.000 M | 388.000 M | 383.000 M | 773.000 M | 520.000 M | |
| Net income basic | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income | 241.000 M | 2.027 B | 1.781 B | 824.000 M | 1.372 B | 1.373 B | 1.564 B | |
| 741.08% | -12.14% | -53.73% | 66.50% | 0.07% | 13.91% |